NeuroScientific Biopharmaceuticals Limited
ASX: NSB.AX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Australian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Nathan Smith
- Employees
- 9
- Headquarters
- Cottesloe, Australia
- IPO year
- 2018
- Market cap
- A$33.3M
- Website
- https://www.neuroscientific.com
Loading NSB…
Loading profile data…Frequently asked questions about NSB
What does NeuroScientific Biopharmaceuticals Limited (NSB.AX) do?
NeuroScientific Biopharmaceuticals Limited develops therapeutic treatments for neurodegenerative diseases through preclinical and clinical studies of patented technologies. Its lead drug candidates include EmtinB for treatment of neurodegenerative dementia and Alzheimer's disease, and degenerative conditions of the optic nerve. The company was i...
Where does NSB.AX trade?
NeuroScientific Biopharmaceuticals Limited (NSB.AX) trades on the Australian Securities Exchange.
What sector is NSB.AX in?
NeuroScientific Biopharmaceuticals Limited (NSB.AX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of NeuroScientific Biopharmaceuticals Limited?
Nathan Smith is the chief executive officer of NeuroScientific Biopharmaceuticals Limited (NSB.AX).
Where is NeuroScientific Biopharmaceuticals Limited headquartered?
NeuroScientific Biopharmaceuticals Limited is headquartered in Australia.
Does NSB.AX pay a dividend?
NeuroScientific Biopharmaceuticals Limited (NSB.AX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did NSB.AX go public?
NeuroScientific Biopharmaceuticals Limited (NSB.AX) completed its initial public offering in 2018.